HRP20190289T1 - Protutijela protiv antigena specifičnog za matične stanice prostate i njihova upotreba - Google Patents
Protutijela protiv antigena specifičnog za matične stanice prostate i njihova upotrebaInfo
- Publication number
- HRP20190289T1 HRP20190289T1 HRP20190289TT HRP20190289T HRP20190289T1 HR P20190289 T1 HRP20190289 T1 HR P20190289T1 HR P20190289T T HRP20190289T T HR P20190289TT HR P20190289 T HRP20190289 T HR P20190289T HR P20190289 T1 HRP20190289 T1 HR P20190289T1
- Authority
- HR
- Croatia
- Prior art keywords
- stemic
- antigenes
- prostate
- stations
- specific
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Engineering & Computer Science (AREA)
- Gynecology & Obstetrics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102011118022.6A DE102011118022B4 (de) | 2011-06-30 | 2011-06-30 | Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung |
| EP12729996.4A EP2726507B1 (de) | 2011-06-30 | 2012-06-29 | Antikörper gegen das prostata-spezifische stammzellantigen und dessen verwendung |
| PCT/EP2012/062716 WO2013001065A1 (de) | 2011-06-30 | 2012-06-29 | Antikörper gegen das prostata-spezifische stammzellantigen und dessen verwendung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20190289T1 true HRP20190289T1 (hr) | 2019-05-03 |
Family
ID=46384405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20190289TT HRP20190289T1 (hr) | 2011-06-30 | 2012-06-29 | Protutijela protiv antigena specifičnog za matične stanice prostate i njihova upotreba |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9200078B2 (enExample) |
| EP (2) | EP3505536B1 (enExample) |
| JP (4) | JP2014528696A (enExample) |
| AU (1) | AU2012277784B2 (enExample) |
| CY (1) | CY1121249T1 (enExample) |
| DE (1) | DE102011118022B4 (enExample) |
| DK (1) | DK2726507T3 (enExample) |
| ES (2) | ES2711978T3 (enExample) |
| HR (1) | HRP20190289T1 (enExample) |
| HU (1) | HUE042008T2 (enExample) |
| LT (1) | LT2726507T (enExample) |
| PL (1) | PL2726507T3 (enExample) |
| PT (1) | PT2726507T (enExample) |
| RS (1) | RS58448B1 (enExample) |
| SI (1) | SI2726507T1 (enExample) |
| SM (1) | SMT201900085T1 (enExample) |
| TR (1) | TR201901991T4 (enExample) |
| WO (1) | WO2013001065A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102011118022B4 (de) * | 2011-06-30 | 2018-01-18 | Gemoab Monoclonals Gmbh | Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung |
| EP2990416B1 (en) | 2014-08-29 | 2018-06-20 | GEMoaB Monoclonals GmbH | Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
| US11834506B2 (en) | 2017-02-08 | 2023-12-05 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind NKG2D, CD16, and a tumor-associated antigen for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| ES2955074T3 (es) | 2017-02-20 | 2023-11-28 | Dragonfly Therapeutics Inc | Proteínas que se unen a HER2, NKG2D Y CD16 |
| WO2019066093A1 (ko) * | 2017-09-26 | 2019-04-04 | 주식회사 와이바이오로직스 | Scf 특이적 항체 |
| ES2986967T3 (es) | 2018-02-08 | 2024-11-13 | Dragonfly Therapeutics Inc | Combinaciones de dominios variables de anticuerpos dirigidas al receptor NKG2D |
| MX2020008333A (es) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales. |
| BR112020016939A2 (pt) | 2018-02-20 | 2020-12-15 | Dragonfly Therapeutics, Inc. | Proteínas de ligação multiespecíficas que se ligam a cd33, nkg2d, e cd16 e métodos de uso |
| KR102835308B1 (ko) | 2018-08-08 | 2025-07-21 | 드래곤플라이 쎄라퓨틱스, 인크. | Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| SG11202100883SA (en) | 2018-08-08 | 2021-02-25 | Dragonfly Therapeutics Inc | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| AU2021268340A1 (en) | 2020-05-06 | 2022-12-08 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16 and CLEC12A |
| AU2021276327A1 (en) * | 2020-05-19 | 2022-12-01 | City Of Hope | Engineered anti-prostate stem cell antigen fusion proteins and uses thereof |
| US12377144B2 (en) | 2021-03-03 | 2025-08-05 | Dragonfly Therapeutics, Inc. | Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen |
| WO2024233662A2 (en) * | 2023-05-09 | 2024-11-14 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Molecules that bind to psca polypeptides |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6541212B2 (en) | 1997-03-10 | 2003-04-01 | The Regents Of The University Of California | Methods for detecting prostate stem cell antigen protein |
| EP2343085B1 (en) * | 1997-03-10 | 2014-12-10 | The Regents of The University of California | Antibody against prostate stem cell antigen (PSCA) |
| ES2309012T3 (es) * | 1999-10-29 | 2008-12-16 | Genentech, Inc. | Composiciones del anticuerpo anti-psca y a sus procedimientos contra celulas cancerigenas que expresen psca. |
| MXPA06004035A (es) * | 2003-10-16 | 2006-08-31 | Micromet Ag | Aglutinantes cd3 de-inmunizados multi-especificos. |
| AU2005250370B2 (en) * | 2004-05-28 | 2010-04-01 | Agensys, Inc. | Antibodies and related molecules that bind to PSCA proteins |
| JP6126773B2 (ja) * | 2007-09-04 | 2017-05-10 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 癌のターゲッティングおよび検出のための高親和性抗前立腺幹細胞抗原（ｐｓｃａ）抗体 |
| SG194399A1 (en) * | 2008-10-01 | 2013-11-29 | Amgen Res Munich Gmbh | Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxcd3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody |
| US20110142811A1 (en) * | 2009-12-16 | 2011-06-16 | Deutsches Krebsforschungszentrum | Measles virus for the elimination of unwanted cell populations |
| DE102011118022B4 (de) * | 2011-06-30 | 2018-01-18 | Gemoab Monoclonals Gmbh | Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung |
-
2011
- 2011-06-30 DE DE102011118022.6A patent/DE102011118022B4/de not_active Expired - Fee Related
-
2012
- 2012-06-29 RS RS20190218A patent/RS58448B1/sr unknown
- 2012-06-29 ES ES12729996T patent/ES2711978T3/es active Active
- 2012-06-29 US US14/129,933 patent/US9200078B2/en active Active
- 2012-06-29 LT LTEP12729996.4T patent/LT2726507T/lt unknown
- 2012-06-29 SI SI201231523T patent/SI2726507T1/sl unknown
- 2012-06-29 TR TR2019/01991T patent/TR201901991T4/tr unknown
- 2012-06-29 HU HUE12729996A patent/HUE042008T2/hu unknown
- 2012-06-29 EP EP18207370.0A patent/EP3505536B1/de active Active
- 2012-06-29 PT PT12729996T patent/PT2726507T/pt unknown
- 2012-06-29 SM SM20190085T patent/SMT201900085T1/it unknown
- 2012-06-29 HR HRP20190289TT patent/HRP20190289T1/hr unknown
- 2012-06-29 ES ES18207370T patent/ES2989975T3/es active Active
- 2012-06-29 WO PCT/EP2012/062716 patent/WO2013001065A1/de not_active Ceased
- 2012-06-29 EP EP12729996.4A patent/EP2726507B1/de active Active
- 2012-06-29 JP JP2014517736A patent/JP2014528696A/ja active Pending
- 2012-06-29 DK DK12729996.4T patent/DK2726507T3/en active
- 2012-06-29 PL PL12729996T patent/PL2726507T3/pl unknown
- 2012-06-29 AU AU2012277784A patent/AU2012277784B2/en not_active Ceased
-
2017
- 2017-01-12 JP JP2017002983A patent/JP6549622B2/ja not_active Expired - Fee Related
-
2019
- 2019-02-11 CY CY20191100176T patent/CY1121249T1/el unknown
- 2019-06-26 JP JP2019117977A patent/JP6886491B2/ja active Active
-
2021
- 2021-05-13 JP JP2021081553A patent/JP7341185B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP6886491B2 (ja) | 2021-06-16 |
| DE102011118022B4 (de) | 2018-01-18 |
| ES2989975T3 (es) | 2024-11-28 |
| JP2021121201A (ja) | 2021-08-26 |
| AU2012277784A1 (en) | 2014-02-06 |
| CY1121249T1 (el) | 2020-05-29 |
| US9200078B2 (en) | 2015-12-01 |
| LT2726507T (lt) | 2019-04-10 |
| DE102011118022A1 (de) | 2013-01-03 |
| PT2726507T (pt) | 2019-02-26 |
| TR201901991T4 (tr) | 2019-03-21 |
| JP6549622B2 (ja) | 2019-07-24 |
| JP2017104113A (ja) | 2017-06-15 |
| US20140134155A1 (en) | 2014-05-15 |
| PL2726507T3 (pl) | 2019-06-28 |
| JP2014528696A (ja) | 2014-10-30 |
| WO2013001065A1 (de) | 2013-01-03 |
| SI2726507T1 (sl) | 2019-05-31 |
| ES2711978T3 (es) | 2019-05-08 |
| HUE042008T2 (hu) | 2019-06-28 |
| EP2726507B1 (de) | 2018-11-21 |
| JP2019193652A (ja) | 2019-11-07 |
| AU2012277784B2 (en) | 2015-08-20 |
| DK2726507T3 (en) | 2019-03-11 |
| EP3505536A1 (de) | 2019-07-03 |
| SMT201900085T1 (it) | 2019-05-10 |
| EP3505536C0 (de) | 2024-08-07 |
| RS58448B1 (sr) | 2019-04-30 |
| JP7341185B2 (ja) | 2023-09-08 |
| EP2726507A1 (de) | 2014-05-07 |
| EP3505536B1 (de) | 2024-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20190289T1 (hr) | Protutijela protiv antigena specifičnog za matične stanice prostate i njihova upotreba | |
| SI2683406T1 (sl) | Protitelesa ANTI-CD40 in njihova uporaba | |
| IL231777A0 (en) | Antibodies against tl1a and uses thereof | |
| HRP20181515T1 (hr) | Mezenhimne stromalne stanice i upotreba povezana s njima | |
| IL231282A0 (en) | Antibodies to 9pcsk and their uses | |
| BR112014012137A2 (pt) | anticorpos anti-fgfr2 e suas utilizações | |
| SI2970456T1 (sl) | Postopki in sestavki za dostavo MRNA-kodiranih protiteles | |
| PL3863288T3 (pl) | Sposoby intra-predykcji i środek nośnikowy | |
| SI2812443T1 (sl) | Protitelesa CD47 in postopki za njihovo uporabo | |
| ME03440B (me) | Cd3-vezujući molekuli sposobni za vezivanje za humani i nehumani cd3 | |
| HRP20182098T1 (hr) | Anti-angptl3 antitijela i njihove primjene | |
| HRP20170713T1 (hr) | Bispecifično anti-igf-1r i anti-erbb3 antitijelo | |
| PL2731677T3 (pl) | Przeciwciała wiążące się z OX40 i ich zastosowania | |
| PL2888284T3 (pl) | Przeciwciała przeciwko haptenom rysperydonu i ich zastosowanie | |
| EP2761554A4 (en) | PAYMENTS IN SOCIAL PROXIMITY | |
| HRP20181457T1 (hr) | Anti-htra1 protutijela i postupci uporabe | |
| PT3462173T (pt) | Anticorpos contra risperidona e utilização dos mesmos | |
| DK3421470T3 (da) | Substituerede 5-fluor-1h-pyrazolopyridiner i krytallinsk form | |
| HRP20171579T8 (hr) | Antigljivična sredstva i njihova upotreba | |
| BR112014013034A2 (pt) | método para produzir um anticorpo | |
| PL2887952T3 (pl) | Przeciwciała przeciwko haptenom olanzapinowym i ich zastosowanie | |
| BR112014002716A2 (pt) | anticorpos anti-poliubiquitina e métodos de uso | |
| BR112014008691A2 (pt) | anticorpos para cd1d | |
| FI20116306L (fi) | Teroitin | |
| HUE037212T2 (hu) | Anti-alfa-V integrin ellenanyag prosztatarák kezelésére |